Therapeutic Potential and Mechanisms of Berberine in Cardiovascular Disease

被引:0
|
作者
Zhang M. [1 ]
Feng L. [1 ]
Li J. [1 ]
Chen L. [1 ]
机构
[1] Department of Pharmacology, College of Basic Medical Sciences, School of Nursing, Jilin University, 126 Xin Min Street, Changchun, 130021, Jilin
关键词
Arrhythmias; Artherosclerosis; Berberine; Heart failure; Hypertension; Ischemia reperfusion heart injury; Stroke;
D O I
10.1007/s40495-016-0070-1
中图分类号
学科分类号
摘要
Berberine is originally isolated from extracts of the Chinese herb Coptis chinensis. It was initially used to treat diarrhea. Over the past two decades, berberine has been shown to be effective for improving glycemic and lipid profiles. Interest in its protective effects against diabetes and cardiovascular risk is beginning to emerge, and research investigating the pharmacological activity of berberine is developing rapidly and being reported internationally. Some clinical evidence has demonstrated the ability of berberine to prevent endothelial dysfunction, myocardial infarction, and arrhythmia in patients with cardiovascular risks. Numerous molecular targets of berberine have been explored, including adenosine monophosphate-activated protein kinase (AMPK), phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT), and NADPH oxidase (NOX). The aim of this review is to focus on the therapeutic potential of berberine in cardiovascular disease and to describe its underlying mechanisms in the pathogenesis of artherosclerosis, hypertension, heart failure, ischemia reperfusion heart injury, stroke, and arrhythmias. © 2016, Springer International Publishing AG.
引用
收藏
页码:281 / 292
页数:11
相关论文
共 50 条
  • [21] MicroRNAs in cardiovascular disease - From disease mechanisms to therapeutic approaches
    Thum, Thomas
    VASCULAR PHARMACOLOGY, 2012, 56 (5-6) : 329 - 330
  • [22] Adrenomedullins and urocortins: Therapeutic potential in cardiovascular disease
    Charles, Christopher J.
    ENDOCRINE JOURNAL, 2010, 57 : S212 - S212
  • [23] Mitochondrial remodeling in cardiovascular disease: Therapeutic potential
    Balachander, Kannan
    Priyadharsini, Jayaseelan Vijayashree
    Paramasivam, Arumugam
    HYPERTENSION RESEARCH, 2023, 46 (02) : 542 - 543
  • [24] Harnessing the Therapeutic Potential of MicroRNAs for Cardiovascular Disease
    Calway, Tyler
    Kim, Gene H.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2015, 20 (02) : 131 - 143
  • [25] Osteopontin in Cardiovascular Disease A Potential Therapeutic Target
    Waller, Alfonso H.
    Sanchez-Ross, Monica
    Kaluski, Edo
    Klapholz, Marc
    CARDIOLOGY IN REVIEW, 2010, 18 (03) : 125 - 131
  • [26] Flavonoids: Potential therapeutic agents for cardiovascular disease
    Liu, Yingxue
    Luo, Jing
    Peng, Lin
    Zhang, Qi
    Rong, Xi
    Luo, Yuhao
    Li, Jiafu
    HELIYON, 2024, 10 (12)
  • [27] Mitochondrial remodeling in cardiovascular disease: Therapeutic potential
    Kannan Balachander
    Jayaseelan Vijayashree Priyadharsini
    Arumugam Paramasivam
    Hypertension Research, 2023, 46 : 542 - 543
  • [28] Astaxanthin: A Potential Therapeutic Agent in Cardiovascular Disease
    Fassett, Robert G.
    Coombes, Jeff S.
    MARINE DRUGS, 2011, 9 (03) : 447 - 465
  • [29] Emodin in cardiovascular disease: The role and therapeutic potential
    Guo, Yuanyuan
    Zhang, Rongzhen
    Li, Wenlan
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [30] Therapeutic potential of apelin and Elabela in cardiovascular disease
    Gao, Shenghan
    Chen, Hongping
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 166